Home GPCR & G Protein Endothelin Receptor

Endothelin Receptor

Isoform-selective Products

Signaling Pathway

Endothelin Receptor Signaling Pathway

Endothelin Receptor Products

  • All (9)
  • Endothelin Receptor Antagonists (9)
  • New Endothelin Receptor Products
Catalog No. Product Name Information Product Use Citations Product Validations
S3051 Bosentan Hydrate Bosentan (Ro 47-0203) is an endothelin (ET) receptor antagonist for ET-A and ET-B with Ki of 4.7 nM and 95 nM, respectively.
Transl Oncol, 2024, 44:101944
Ann Dermatol, 2024, 36(3):151-162
Cancer Sci, 2023, 114(2):640-653
S8051 Macitentan Macitentan is an orally active, non-peptide, dual ETA/ETB (endothelin) receptor antagonist with IC50 of 0.5 nM/391 nM.
Biomedicines, 2022, 10(3)629
Front Pharmacol, 2021, 12:740529
Front Med (Lausanne), 2021, 8:742436
S7883 BQ-123 BQ-123 is a selective endothelin A receptor (ETA) antagonist with IC50 of 7.3 nM. Phase 2.
Baghdad Science Journal, 2023, 20(5 Suppl.)
J Mol Cell Cardiol, 2022, 171:16-29
BioMed Research International, 2019-, 10.1155/2019/3851718
S1456 Zibotentan (ZD4054) Zibotentan (ZD4054) is a specific Endothelin (ET)A antagonist with IC50 of 21 nM, exhibiting no activity at ETB. Phase 3.
Cell Death Dis, 2023, 14(1):5
Hepatology, 2016, 63(3):1000-12
Oncotarget, 2016, 7(47):77138-77151
S2097 Ambrisentan Ambrisentan (LU-208075, BSF-208075) is a highly selective antagonist of the endothelin-1 type A receptor, used in the treatment of pulmonary arterial hypertension (PAH).
Eur J Pharmacol, 2019, 855:124-136
Pharmacol Res Perspect, 2017, 5(6)
S4220New Bosentan Bosentan is an endothelin (ET) receptor antagonist for ET-A and ET-B with Ki of 4.7 nM and 95 nM, respectively.
Oncotarget, 2016, 7(20):29187-98
PLoS One, 2016, 11(9):e0161988
S6665 Sparsentan (PS-433540, RE-021) Sparsentan (PS-433540, RE-021, DARA) is a dual endothelin type A receptor(ETA) and angiotensin II type 1 receptor antagonist.
Front Pharmacol, 2022, 13:964370
Biomedicines, 2021, 10(1)86
S0017 Lu-135252 Lu-135252 (Darusentan,HMR-4005) is a selective endothelin A receptor (ET-A receptor) antagonist indicated for the oral treatment of resistant hypertension.
E3868 Pearl Extract Pearl Extract is extracted from pearl, which inhibits endothelin, thereby safely and effectively lightening the skin by antagonising endothelin.
S3051 Bosentan Hydrate Bosentan (Ro 47-0203) is an endothelin (ET) receptor antagonist for ET-A and ET-B with Ki of 4.7 nM and 95 nM, respectively.
Transl Oncol, 2024, 44:101944
Ann Dermatol, 2024, 36(3):151-162
Cancer Sci, 2023, 114(2):640-653
S8051 Macitentan Macitentan is an orally active, non-peptide, dual ETA/ETB (endothelin) receptor antagonist with IC50 of 0.5 nM/391 nM.
Biomedicines, 2022, 10(3)629
Front Pharmacol, 2021, 12:740529
Front Med (Lausanne), 2021, 8:742436
S7883 BQ-123 BQ-123 is a selective endothelin A receptor (ETA) antagonist with IC50 of 7.3 nM. Phase 2.
Baghdad Science Journal, 2023, 20(5 Suppl.)
J Mol Cell Cardiol, 2022, 171:16-29
BioMed Research International, 2019-, 10.1155/2019/3851718
S1456 Zibotentan (ZD4054) Zibotentan (ZD4054) is a specific Endothelin (ET)A antagonist with IC50 of 21 nM, exhibiting no activity at ETB. Phase 3.
Cell Death Dis, 2023, 14(1):5
Hepatology, 2016, 63(3):1000-12
Oncotarget, 2016, 7(47):77138-77151
S2097 Ambrisentan Ambrisentan (LU-208075, BSF-208075) is a highly selective antagonist of the endothelin-1 type A receptor, used in the treatment of pulmonary arterial hypertension (PAH).
Eur J Pharmacol, 2019, 855:124-136
Pharmacol Res Perspect, 2017, 5(6)
S4220New Bosentan Bosentan is an endothelin (ET) receptor antagonist for ET-A and ET-B with Ki of 4.7 nM and 95 nM, respectively.
Oncotarget, 2016, 7(20):29187-98
PLoS One, 2016, 11(9):e0161988
S6665 Sparsentan (PS-433540, RE-021) Sparsentan (PS-433540, RE-021, DARA) is a dual endothelin type A receptor(ETA) and angiotensin II type 1 receptor antagonist.
Front Pharmacol, 2022, 13:964370
Biomedicines, 2021, 10(1)86
S0017 Lu-135252 Lu-135252 (Darusentan,HMR-4005) is a selective endothelin A receptor (ET-A receptor) antagonist indicated for the oral treatment of resistant hypertension.
E3868 Pearl Extract Pearl Extract is extracted from pearl, which inhibits endothelin, thereby safely and effectively lightening the skin by antagonising endothelin.
S4220New Bosentan Bosentan is an endothelin (ET) receptor antagonist for ET-A and ET-B with Ki of 4.7 nM and 95 nM, respectively.
Oncotarget, 2016, 7(20):29187-98
PLoS One, 2016, 11(9):e0161988

Choose Selective Endothelin Receptor Inhibitors

Tags: Endothelin Receptor inhibitor|Endothelin Receptor agonist|Endothelin Receptor activator|Endothelin Receptor inducer|Endothelin Receptor antagonist|Endothelin Receptor signaling pathway|Endothelin Receptor assay kit